Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2002 1
2006 1
2007 1
2012 2
2013 3
2014 3
2015 1
2020 1
2024 1
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.
Kim WS, Kim TM, Cho SG, Jarque I, Iskierka-Jażdżewska E, Poon LM, Prince HM, Zhang H, Cao J, Zhang M, Tessoulin B, Oh SY, Lim F, Carpio C, Tan TD, Ayyappan S, Gutierrez A, Cai J, Ufkin M, Shariff S, Brouwer-Visser J, Chaudhry A, Mohamed H, Ambati S, Walewski J; ELM-2 Investigators. Kim WS, et al. Nat Cancer. 2025 Mar;6(3):528-539. doi: 10.1038/s43018-025-00921-6. Epub 2025 Mar 17. Nat Cancer. 2025. PMID: 40097657 Free PMC article. Clinical Trial.
Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.
Kim WS, Kim TM, Cho SG, Jarque I, Iskierka-Jażdżewska E, Poon LM, Prince HM, Zhang H, Cao J, Zhang M, Tessoulin B, Oh SY, Lim F, Carpio C, Tan TD, Ayyappan S, Gutierrez A, Cai J, Ufkin M, Shariff S, Brouwer-Visser J, Chaudhry A, Mohamed H, Ambati S, Walewski J; ELM-2 Investigators. Kim WS, et al. Nat Cancer. 2025 May;6(5):907. doi: 10.1038/s43018-025-00967-6. Nat Cancer. 2025. PMID: 40240622 Free PMC article. No abstract available.
Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas.
Soumerai JD, Diefenbach CS, Jagadeesh D, Asch A, Kumar A, Tsai ML, Jandl TA, Lossos IS, Kenkre VP, Awan F, Novotny W, Huang J, Miao L, Rajagopalan P, Ghalie RG, Zelenetz AD. Soumerai JD, et al. Among authors: jandl ta. Br J Haematol. 2024 May;204(5):1762-1770. doi: 10.1111/bjh.19419. Epub 2024 Mar 19. Br J Haematol. 2024. PMID: 38500476 Free PMC article. Clinical Trial.
Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients.
Tremblay D, Seah C, Schneider T, Bhalla S, Feld J, Naymagon L, Wang B, Patel V, Jun T, Jandl T, Rahman F, Liu STH, Aberg JA, Bouvier N; Mount Sinai Health System Convalescent Plasma Team. Tremblay D, et al. Among authors: jandl t. Cancer Med. 2020 Nov;9(22):8571-8578. doi: 10.1002/cam4.3457. Epub 2020 Sep 17. Cancer Med. 2020. PMID: 32945149 Free PMC article.
Compton scattering by internal shields based on melanin-containing mushrooms provides protection of gastrointestinal tract from ionizing radiation.
Revskaya E, Chu P, Howell RC, Schweitzer AD, Bryan RA, Harris M, Gerfen G, Jiang Z, Jandl T, Kim K, Ting LM, Sellers RS, Dadachova E, Casadevall A. Revskaya E, et al. Among authors: jandl t. Cancer Biother Radiopharm. 2012 Nov;27(9):570-6. doi: 10.1089/cbr.2012.1318. Cancer Biother Radiopharm. 2012. PMID: 23113595 Free PMC article.
Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma.
Pashenkov M, Goëss G, Wagner C, Hörmann M, Jandl T, Moser A, Britten CM, Smolle J, Koller S, Mauch C, Tantcheva-Poor I, Grabbe S, Loquai C, Esser S, Franckson T, Schneeberger A, Haarmann C, Krieg AM, Stingl G, Wagner SN. Pashenkov M, et al. Among authors: jandl t. J Clin Oncol. 2006 Dec 20;24(36):5716-24. doi: 10.1200/JCO.2006.07.9129. J Clin Oncol. 2006. PMID: 17179105 Clinical Trial.
15 results